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Background The clonal diversity underpinning trends in multidrug resistant Escherichia coli causing bloodstream 
infections remains uncertain. We aimed to determine the contribution of individual clones to resistance over time, 
using large-scale genomics-based molecular epidemiology.
Methods This was a longitudinal, E coli population, genomic, cohort study that sampled isolates from 22 512 E coli 
bloodstream infections included in the Norwegian surveillance programme on resistant microbes (NORM) from 
2002 to 2017. 15 of 22 laboratories were able to share their isolates, and the first 22·5% of isolates from each year were 
requested. We used whole genome sequencing to infer the population structure (PopPUNK), and we investigated the 
clade composition of the dominant multidrug resistant clonal complex (CC)131 using genetic markers previously 
reported for sequence type (ST)131, effective population size (BEAST), and presence of determinants of antimicrobial 
resistance (ARIBA, PointFinder, and ResFinder databases) over time. We compared these features between the 
2002–10 and 2011–17 time periods. We also compared our results with those of a longitudinal study from the UK done 
between 2001 and 2011.
Findings Of the 3500 isolates requested from the participating laboratories, 3397 (97·1%) were received, of which 
3254 (95·8%) were successfully sequenced and included in the analysis. A significant increase in the number of 
multidrug resistant CC131 isolates from 71 (5·6%) of 1277 in 2002–10 to 207 (10·5%) of 1977 in 2011–17 (p<0·0001), 
was the largest clonal expansion. CC131 was the most common clone in extended-spectrum β-lactamase 
(ESBL)-positive isolates (75 [58·6%] of 128) and fluoroquinolone non-susceptible isolates (148 [39·2%] of 378). Within 
CC131, clade A increased in prevalence from 2002, whereas the global multidrug resistant clade C2 was not observed 
until 2007. Multiple de-novo acquisitions of both blaCTX-M ESBL-encoding genes in clades A and C1 and gain of 
phenotypic fluoroquinolone non-susceptibility across the clade A phylogeny were observed. We estimated that 
exponential increases in the effective population sizes of clades A, C1, and C2 occurred in the mid-2000s, and in clade 
B a decade earlier. The rate of increase in the estimated effective population size of clade A (Ne=3147) was nearly 
ten-times that of C2 (Ne=345), with clade A over-represented in Norwegian CC131 isolates (75 [27·0%] of 278) 
compared with the UK study (8 [5·4%] of 147 isolates).
Interpretation The early and sustained establishment of predominantly antimicrobial susceptible CC131 clade A 
isolates, relative to multidrug resistant clade C2 isolates, suggests that resistance is not necessary for clonal success. 
However, even in the low antibiotic use setting of Norway, resistance to important antimicrobial classes has rapidly 
been selected for in CC131 clade A isolates. This study shows the importance of genomic surveillance in uncovering 
the complex ecology underlying multidrug resistance dissemination and competition, which have implications for 
the design of strategies and interventions to control the spread of high-risk multidrug resistant clones.
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Introduction
Escherichia coli is a commensal of the gastrointestinal 
tract and a leading cause of bloodstream infections 
worldwide, which is associated with considerable 
morbidity and mortality.1 E coli associated with 
bloodstream infections are a subset of extraintestinal 
pathogenic E coli (ExPEC), with bloodstream infections 
occurring as a result of underlying urinary tract 
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infection, gastrointestinal colonisation, or hepatobiliary 
infections.2 Although most ExPEC belong to phylo­
group B2 they are not a monophyletic group; ExPEC are 
a diverse collection of clones with the capacity to invade 
and cause disease through the acquisition of virulence 
factors.3 A small number of globally dispersed ExPEC 
clones are responsible for most infections,4 and increases 
in the incidence of E coli-associated bloodstream 
infections have been reported in multiple countries.5–7 
Increasing incidence is exacerbated by an increasing 
proportion of multidrug resistant ExPEC infections.5–7 
One study estimated that E coli resistant to third 
generation cephalosporins caused 25–43 million cases of 
bloodstream infections and other serious infections 
globally in 2014.8
In 2014, a single ExPEC clone—clonal complex 
(CC)131—was reported to predominate globally.9 A 
retrospective genomic study of bloodstream infections in 
the UK showed that CC131 had emerged quickly around 
2003.10 Whole genome sequencing has allowed the 
delineation of a number of phylogenetic subgroups—
known as clades—within CC131; each clade has different 
associations with antimicrobial resistance.11–13 Clades C1 
(alternatively referred to as H30­R) and C2 (H30­Rx) 
are characterised by fluoroquinolone resistance. Clade C2 
is also associated with extended­spectrum β­lacta mases 
(ESBL) of the CTX­M class conferring resistance to third 
generation cephalosporins.11–13 Clades C1 and C2 were 
reported to be the leading cause of multidrug resistant 
E coli infections in the USA in 2011–12.6 Additional CC131 
clades—A, B, B0, and C0—have been reported as minor 
clades with less resistance.11–13
Much of the literature proposes that antimicrobial 
resistance might have driven the emergence and success 
of CC131. However, there are other successful E coli 
bloodstream infections clones—including CC73 and 
CC95—that have less extensive antimicrobial resistance.10 
Evidence suggests that success, through competition 
between E coli strains, is a product of the relative 
frequency of the full complement of accessory genes, not 
just antimicrobial resistance, termed negative frequency­
dependent selection.10,14
E coli bloodstream infections have been increasing 
in Norway, with the prevalence of ESBL­producing 
and fluoroquinolone non­susceptible E coli causing 
bloodstream infections also increasing.5 We used whole 
genome sequencing to analyse the clonal diversity of E coli 
causing bloodstream infections in Norway over 16 years. 
This large nationwide longitudinal genomic collection 
allowed us to observe the emergence of clones and determine 
their contribution to rising bloodstream infections inci­
dence and antimicrobial resistance prevalence.
Research in context
Evidence before this study
Following initial reports in the early 2000s, numerous 
surveillance and epidemiological studies have reported 
Escherichia coli clonal complex (CC)131 as the dominant cause of 
E coli urinary tract and bloodstream infections worldwide. 
We searched PubMed from inception of the database to 
May 22, 2020, with the search terms “coli” AND “ST131” AND 
“infection” AND “urinary” OR “blood”. Searches were restricted to 
primary research articles published in English. This returned a 
total of 957 publications describing the isolation and relative 
frequency of CC131 in urinary tract infections and bloodstream 
infections. Of these, only one was designed as a longitudinal 
survey of isolates on a UK collection of bloodstream infections 
E coli isolates in 2001–11 from the British Society for 
Antimicrobial Chemotherapy. By doing a densely sampled 
longitudinal study, the team behind the UK collection were able 
to conclude that although CC131 increased in frequency in the 
early 2000s, this increase was not as large as suggested by 
previous single-site, single-timepoint studies. The study also 
suggested that multidrug resistance alone did not explain the 
increase in CC131 prevalence, a finding supported by a 
subsequent evolutionary genomics study in 2019. Thus, a 
number of important questions remain regarding the 
epidemiology of E coli from bloodstream infections, including 
whether the results of the UK study are representative of the 
wider geographical picture and what has happened to the E coli 
population from bloodstream infections after 2011.
Added value of this study
Our study used a longitudinal sampling framework over an 
extended period of 16 years that provides a clear picture of the 
underlying epidemiology of E coli from bloodstream infections. 
By doing this in another country, we had the opportunity to 
compare the findings with the longitudinal UK study and 
determine whether the findings in one setting were 
generalisable, even when antimicrobial usage and resistance 
differs. These data also allowed for comparisons of the growth 
and expansion of clones that cause bloodstream infections 
beyond the raw prevalence numbers available at any one time.
Implications of all the available evidence
A full picture of the emergence of E coli as a major cause of 
bloodstream infections is required, driven by longitudinal 
understanding of the epidemiology and multidrug resistance of 
these organisms. Our data suggests that CC131 clade A is an 
increasingly common cause of multidrug resistance bloodstream 
infections, which is a novel finding not reported in previous 
studies and merits surveillance for this clone worldwide. 
This study shows that the findings of individual, longitudinal 
surveys of E coli epidemiology are not generalisable across 
countries, not even between resource-similar nations within 
Europe. The observation of both emerging multidrug resistant 
clones and the acquisition of multidrug resistance in established 
clones, has implications for our efforts to control multidrug 
resistance in this pathogen.
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Methods
Study design and bacterial isolates
In this nationwide, longitudinal, microbial population 
genomic study, a dataset of all 22 512 E coli isolates collected 
from 2002 to 2017, as part of the Norwegian surveillance 
programme on resistant microbes (NORM), was collated.5 
Sample identifier, laboratory, year, sample collection date, 
and antimicrobial susceptibility profile were reported for 
each isolate. We selected the first 22·5% of isolates 
annually from 15 of the 22 laboratories participating in 
NORM to fill our capacity to sequence 3500 isolates. 
(appendix 1 pp 1, 6). The collection of data within NORM 
follows a standard protocol defined in the yearly 
surveillance reports (appendix 1 p 1).5
Procedures
Isolates were plated on MacConkey agar no 3 (Oxoid, 
Thermo Fisher Scientific, Waltham, MA, USA); one 
colony was subsequently used to inoculate 1·6 mL Luria 
Bertani broth (Becton Dickinson, NJ, USA) and 
incubated overnight at 37°C. Genomic DNA was extracted 
by QIAGEN (Hilden, Germany) with the DNeasy 
96 Blood and Tissue kit (QIAGEN, Hilden, Germany). 
Samples were sequenced at the Wellcome Sanger 
Institute (Hinxton, UK) on the Illumina HiSeq platform 
(San Diego, CA, USA) using the NEB Ultra II custom kit 
(Emsworth, UK) with 392­plexing and a 150 base­pair 
read length. Samples failed quality control if there was 
insufficient DNA to be sequenced, depth of coverage was 
less than 20, or there was evidence of mixed strain or 
species contamination. Sequence data are available 
on the European Nucleotide Archive (appendix 2). 
Data in NORM are disidentified. Ethics approval was not 
required after evaluation by the Regional Ethical 
Committee (REC North 93528).
Genome sequences were assembled and annotated 
using default parameters of a published pipeline,15,16 
and the pangenome was defined using Panaroo 
(version 1.0.2).17 Phylogenetic group and multilocus 
sequence type were determined using published tools 
(appendix pp 2–3).18,19 PopPUNK (version 2.0.2) was used to 
cluster isolates with shared ancestry into clones.20 We 
defined a CC as the most prevalent sequence type (ST) 
within a PopPUNK grouping. ARIBA (version 2.12.2) was 
used with ResFinder and PointFinder (E coli) databases21,22 
to detect bacterial resistance determinants, including 
blaCTX­M genes and fluoroquinolone resistance associated 
mutations in gyrA, parC, or parE.21–23 blaCTX­M genes served as 
a proxy for ESBL­production and mutations in genes 
associated with ciprofloxacin efflux were screened for in 
the Panaroo gene alignments.24–26
PopPUNK4 (CC131) isolates were mapped to 
EC958 (GenBank HG941718.1) and recombination was 
detected and removed using GUBBINS (version 2.4.0). 
A recombination­free phylogeny was produced with 
RAxML (version 8.2.8).27,28 CC131 clades were assigned 
using clade­specific single nucleotide polymorphism and 
fimH alleles, and then corrected for the phylogenetic 
distribution of clades.11–13 K­mers associated with recombi­
nation hotspots were excluded before generating 
a reference­free alignment with SKA (version 1.0) 
for each CC131 clade.29 BEAST (version 1.10.4) was 
subsequently used with the generalised time reversible 
substitution and gamma site heterogeneity models for 
100 000 000 generations, with 10% discarded as burn­in, 
sampled every 10 000 states.30 External collections of E coli 
CC131 genomes used by McNally and colleagues14 and a 
longitudinal collection of bloodstream infections10 were 
used to compare with Norwegian isolates, the fastq data 
was processed using the methods we described here. 
Additional details on isolate culturing; DNA extraction, 
sequencing, and annotation; and genome sequence 
analyses are described in appendix 1 (pp 1–4).
Statistical analysis
To determine if differences in proportions between two 
groups were significant two­sided Fisher’s exact test was 
used when any counts were less than five, otherwise 
χ² test was used. Both tests had a p<0·05 threshold. We 
split the collection into two periods (2002–10 and 2011–17) 
to assess differences in proportions to reduce any bias 
contained in any one year. We chose to split between 2010 
and 2011 because this was approximately the half way 
point of the sample collection period and because we 
observed that many key changes occurred after 2010. 
Using these two periods we compared the prevalence of 
popPUNK4­CC131 as a proportion of the collection, each 
CC131 clade as a proportion of the collection, and of 
each CC131 clade within CC131. We also compared the 
overall prevalence of blaCTX­M­positive and ciprofloxacin 
non­susceptible CC131 isolates (on the basis of NORM 
data) and compared the isolates that belonged to each 
clade of CC131 as proportion of the collection, as a 
proportion of CC131, and as a proportion of each CC131 
clade. Additionally, we compared the prevalence of 
CC131, and the prevalence of blaCTX­M­positive and 
ciprofloxacin non­susceptible isolates between different 
health regions in Norway. Finally, we compared the 
prevalence of CC131, each CC131 clade, blaCTX­M­positive 
isolates, and isolates in which gyrA or parC mutations 
associated with reduced ciprofloxacin susceptibility were 
detected, between our study and a UK study.10 The BEAST 
Bayesian skyline model, which uses phylogenetic history 
to provide estimates of the median effective population 
size over time with a 95% highest posterior density, was 
used to identify the main exponential increase in 
population size and the slope representing the rate of 
increase in each clade (appendix p 4). To assess the 
relative invasiveness of CC131 clades we used the ratio of 
effective population size and incidence in bloodstream 
infections in 2017. The incidence of each clade was 
estimated from the isolate counts adjusted for the 
proportion of total E coli bloodstream infections in 2017 
that was sampled in this study, reported per million 
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population. Statistical analyses were done with R 
(version 3.6.3).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
The 15 laboratories contributing to NORM provided 
15 552 samples collected from 2002 to 2017, of which we 
selected 3500 (22·5%) for inclusion. Of the 3500 isolates, 
3397 (97·1%) were received and sequenced. 3254 (95·8%) 
passed sequencing quality control criteria and had a 
mean sequencing depth of 52·1 (SD 9·9). Excluded 
samples had no effect on the interpretation of the results 
(appendix 1 p 5). 1277 (39·2%) of 3254 samples were 
from the first half of the study (2002–10) and 1977 (60·8%) 
samples were from the second half of the study (2011–17).
2180 (67·0%) of 3254 samples belonged to 
phylo group B2. The collection was delineated into 
136 clonal groups by PopPUNK (appendix 1 p 7). 
PopPUNK1 (CC73), PopPUNK2 (CC95), PopPUNK3 
(CC69), PopPUNK4 (CC131), and PopPUNK5 (CC14) 
were the most common clones, accounting for 
1761 (54·1%) of 3254 samples. CC131 showed the largest 
proportional gain in the collection between 2002 and 2017, 
occurring gradually from 2002 to its peak prevalence 
in 2013 (figure 1; appendix 1 p 8), with a significant 
increase between 2002–10 (71 [5·6%] of 1277 samples) and 
2011–17 (207 [10·5%] of 1977 samples; p<0·0001; 
figure 1A). CC131 clades A (p=0·0043), C1 (p=0·0002), 
and C2 (p=0·0009) increased as a proportion of the 
collection between 2002 and 2010 and 2011 and 2017, 
while clade B remained stable (p=0·55; figure 1B; 
appendix 1 p 18). Clades B0 and C0 combined were 
present in eight (2·9%) of 278 CC131 samples 
(appendix 1 p 9). Within CC131, we only detected a change 
in proportion for clade B, which significantly decreased as 
a proportion of CC131 between 2002 and 2010 (32 [45·1%] 
of 71 samples) and 2011–17 (42 [20·3%] of 207 samples; 
p=0·0001; appendix 1 p 18).
We considered CTX­M­encoding genes to be markers for 
ESBL­production and detected nine blaCTX­M variants in 
128 (3·9%) of 3254 isolates (appendix 1 p 10). We did not 
detect a significant difference in blaCTX­M gene prevalence 
between 2002 (one [1·2%] of 83 isolates) and the peak 
prevalence in 2016 (21 [7·0%] of 300; p=0·058). CC131 was 
the single largest contributor of blaCTX­M­positive isolates in 
the collection (75 [58·6%] of 128 isolates; figure 2A). The 
remaining 53 (41·4%) CTX­M positive isolates belonged to 
18 other PopPUNK clones. The number of clones with 
blaCTX­M­positive isolates in 2017 was not significantly 
different to 2002 (p=0·19). Clades C2, C1, and A accounted 
for all CC131 blaCTX­M­positive isolates and for more than 
half (71 [63·4%]) of all 112 blaCTX­M­positive isolates during 
2011–17 (C2: 33 [29·5%]; C1: 27 [24·1%]; and A: 11 [9·8%]; 
figure 2B). blaCTX­M­positive isolates increased significantly 
overall in the 2002–10 and 2011–17 periods, as did 
blaCTX­M­positive isolates that belonged to CC131 and to the 
CC131 clades C1, C2, and A as a proportion of the collection 
(appendix 1 p 19). Clade C2 had the highest proportion of 
blaCTX­M­positive isolates (33 [76·7%] of 43) in 2011–17.
blaCTX­M­15 was the most common blaCTX­M type 
(appendix p 10). Within CC131, 36 (70·6%) of 51 clade C2 
isolates were blaCTX­M­15­positive, and one (2·0%) of 51 clade 
C2 isolates was blaCTX­M­89­positive. The most common 
blaCTX­M type in clade C1 was blaCTX­M­27 (15 [21·4%] of 
70 isolates). blaCTX­M­15 (7 [9·3%] of 75 isolates) was the most 
common in clade A (appendix 1 p 20). All 74 clade B isolates 
were blaCTX­M­negative. De­novo blaCTX­M acquisitions were 
observed in clades A and C1 (appendix 1 pp 11–13). Within 
clade C1 we estimated that there were nine phylogenetically 
independent acquisitions of blaCTX­M genes contributing to 
the 27 blaCTX­M­positive isolates. A single acquisition of 
blaCTX­M­27 accounted for 14 (51·9%) of the 27 isolates. 
However, most acquisitions (five [55·6%] of nine) were 
detected in a single isolate. Within clade A we estimated 
that around seven de­novo acquisitions of CTX­M­encoding 
genes accounted for most blaCTX­M­positive isolates, with 
most acquisitions (four [57·1%] of seven) detected in only 
one isolate and all acquisitions detected in a maximum of 
two isolates.
Ciprofloxacin non­susceptibility (determined on the 
basis of susceptibility profiles from NORM) was observed 
in 378 (11·6%) of 3254 isolates, increasing from three 
(3·6%) of 83 isolates in 2002 to a peak of 67 (18·9%) of 
355 isolates in 2017. There was a significant increase 
from 77 (6·0%) of 1277 isolates during the 2002–10 period 
to 301 (15·2%) of 1977 isolates during the 2011–17 
(p<0·0001). Only 94 (24·9%) of 378 ciprofloxacin non­
susceptible isolates were also blaCTX­M­positive, whereas 
most (94 [73·4%] of 128 isolates) of blaCTX­M­positive 
isolates were also ciprofloxacin non­susceptible. CC131 
made the single largest contri bution to cipro floxacin 
non­susceptibility in the collection, contributing 148 
(39·2%) of 378 isolates overall and 25 (37·3%) of 
67 isolates in 2017 alone. CC131, CC14, and CC69 
combined accounted for 41 (61·2%) of 67 ciprofloxacin 
non­susceptible isolates in 2017. The remaining 26 
(38·8%) belonged to 34 other PopPUNK clones 
(figure 3A). Of the 301 ciprofloxacin non­susceptible 
isolates reported between 2011 and 2017, 53 (17·6%) were 
CC131 clade C1, 42 (14·0%) were clade C2 contributed, 
and 25 (8·3%) were clade A. The proportion of isolates 
with cipro floxacin non­susceptibility within CC131 
significantly increased (p=0·0002) between 2002–10 and 
2011–17 (figure 3B; appendix 1 pp 14, 21). Clades C1 
and C2 were near uniformly ciprofloxacin resistant 
(114 [94·2%] of 121 isolates) and all had Ser83Leu and 
Asp87Asn substitutions in GyrA and Ser80Ile and 
Glu84Val substitutions in ParC. The non­susceptible 
phenotypes in clade A were represented by multiple 
independent phylogenetic clusters and were not well 
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explained by detected mutations in gyrA, parC, or parE 
listed in the PointFinder (E coli) resistance database 
(appendix 1 p 15). 23 (82·1%) of the 28 ciprofloxacin non­
susceptible isolates in clade A had resistance mutations 
in gyrA but not parC, and most clade A isolates (71 [94·7%] 
of 75) had the ParE Ile529Leu substitution regardless of 
phenotype. Non­susceptible isolates in clade A did not 
have known mutations in efflux­associated genes, 
pump­encoding genes, or plasmid­mediated quinolone 
resistance genes.
Figure 1: Proportion of isolates by clone and by CC131 clades over time
(A) Clones as a proportion of all 3254 isolates by year. CC131 had the largest gain of all lineages as proportion of the collection between 2002 and 2017. (B) CC131 and 
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We estimated an exponential increase in the effective 
population sizes of clades A, C1, and C2 in the mid­2000s, 
whereas the increase in clade B occurred more than a 
decade earlier, around 1990 (figure 4). The rate of expansion 
of the effective population size over time (per year) in the 
exponential phase was estimated to be nearly ten­times 
higher for clade A (Ne=3147) than for clade C2 (Ne=345) and 
nearly 25­times higher than for C1 (Ne=131; figure 4; table).
These four clades (A, B, C1, and C2) each accounted for 
about 2–3% of the collection in 2017 and were estimated 
(adjusting for sampling) to have similar bloodstream 
infections incidence per million population in Norway 
Figure 2: Proportion blaCTX-M-positive isolates by clone and by CC131 clades over time
(A) The 128 blaCTX-M-positive isolates by clone as a proportion of all 3254 isolates by year. (B) blaCTX-M-positive isolates in CC131 (n=75) by clade as a proportion of the 
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Figure 3: Proportion of isolates that were ciprofloxacin non-susceptible by clone and by CC131 clades over time
(A) 378 ciprofloxacin non-susceptible isolates by clone as a proportion of all 3254 isolates by year. CC131 made the single largest contribution of any clone to 
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in 2017 (table; appendix 1 pp 4, 22). The ratio of each 
clade’s estimated population size (used as a proxy for the 
carriage population) to incidence of disease (bloodstream 
infections) in the human population was used as a 
measure of invasiveness relative to the other clades. For 
clades C1 and C2 we estimated smaller population sizes 
and higher population size to incidence ratios, whereas 
clade A had the largest population size and lowest ratio. 
The time to the most recent common ancestors of our 
Norwegian isolates in CC131 clades C1 and C2 predate 
the study period by more than a decade, whereas clades A 
and B are estimated to be older (table).
There was no discernible spatiotemporal spread or 
phylogenetic structure within Norway during the 
expansion of CC131 (appendix 1 pp 16, 23). In 2002, clade 
A was already observed in blood cultures in the north and 
west health regions. C2 was the most recently observed 
clade in bloodstream infections: first reported in 2007. 
CC131 (p=0·031) and blaCTX­M­positive isolates (p=0·032) 
were significantly under­represented in the central health 
region compared with the rest of the collection. 
Ciprofloxacin resistance was under­represented in the 
north (p=0·041) and over­represented in the southeast 
(p=0·015; appendix 1 p 24).
Prevalence of CC131 in our collection was compared 
with CC131 isolates from another longitudinal collection 
from the UK, representing isolates from 2002–11.10 
Compared with the UK, a significantly larger proportion of 
Norwegian CC131 isolates belonged to clade A (UK 8 [5·4%] 
of 147 isolates vs Norway 75 [27·0%] of 278 isolates; 
p<0·0001) and clade C1 (UK 12 [8·2%] of 147 vs Norway 
70 [25·2%] of 278; p<0·0001; appendix 1 pp 25–27). The 
Figure 4: Bayesian skyline plots of estimated median effective population size of clonal complex 131 clades A, B, C1, and C2 over time
Shaded areas indicate 95% highest posterior density intervals.
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opposite was true for clade C2 (UK 89 [60·5%] of 147 vs 
Norway 51 [18·3%] of 278; p<0.0001). As such, resistant 
isolates within these clades made different contributions 
to resistance between the two countries. Clade C2 made a 
significantly smaller contribution (p<0·0001), and 
clades C1 and A made significantly larger contributions to 
both CC131 blaCTX­M­positive isolates (C1 p<0·0001 and 
A p=0·0028), and CC131 isolates with gyrA and parC 
mutations (C1 p<0·0001 and A p<0·0001) in Norway than 
in the UK (appendix 1 pp 26–27).
Finally, we contextualised our Norwegian isolates 
within a global genomic collection.14 Aside from the 
over­representation of Norwegian isolates in clade A and 
under­representation in clade C2, Norwegian isolates 
were phylogenetically spread across the sampled genetic 
diversity from other locations within each of the CC131 
clades (appendix 1 p 17).
Discussion
Cases of E coli bloodstream infections have been 
increasing in Norway, the UK, and elsewhere.5,7 Of 
greater concern is the increasing proportion of 
bloodstream infections caused by multidrug resistant 
isolates. ESBL prevalence in E coli bloodstream infections 
in Norway increased from 0·3% in 2002 to 6·6% by 2017.5 
Fluoroquinolone resistance in Norway has also continued 
to increase from 3·3% in 2002 to 18·0% in E coli causing 
bloodstream infections in 2017.5 We observed similar 
prevalence and general increasing trends. A clear 
correlation between the total usage of fluoroquinolones 
and non­susceptibility to these drugs has been reported 
in Norway, where anti microbial usage in both animals 
and people is generally low and tightly regulated.5
Our data show the emergence of CC131 as the dominant 
contributor to the prevalence of ESBLs and fluoroquinolone 
resistance in E coli causing bloodstream infections in 
Norway. The emergence of CC131 in Norway appears to 
have been a gradual process spanning 2002–13 compared 
with that reported for the UK where the expansion 
occurred quickly between 2002–04.10 Additionally, we show 
that the prevalence of the individual CC131 clades are 
different between the two countries, with a higher 
prevalence and resistance for clade A and C1 and lower 
prevalence and resistance in C2 in Norway. Despite these 
differences we detected the same predominant CC131 
blaCTX­M types reported by others: blaCTX­M­15 in clade C2, and 
blaCTX­M­27 and blaCTX­M­14 in clade C1.10,31 Moreover, the CC131 
diversity we observed overlapped with other datasets, and 
our estimated time to most recent common ancestor for 
CC131 clades are in line with previous estimates.11–13,31,32
Of note, in Norway, CC131 clades have different 
antimicrobial resistance prevalence, estimated population 
sizes, growth rates, and potentially invasiveness. In­vivo 
quantification of clade virulence combined with genomics 
could reveal underlying variation driving any differences 
in invasiveness. Evidence of varying evolutionary pressures 
also warrants elaboration of the negative frequency­
dependent selection model for ExPEC population 
evolution.14 Although responsible for less resistance than 
the multidrug resistant clade C2, increasing resistance 
facilitated by multiple de­novo acquisition events in other 
clades of CC131 is of clinical concern. Clade A, which was 
the most frequently observed clade during the study 
period, and clade B are far less resistant than clade C2 
suggesting drug resistance is not essential for their 
success. Furthermore, we show resistance being acquired 
multiple times sporadically within clades A and C1. The 
clades expanded without preferential expasion of the 
resistant isolates, which again suggest resistance is being 
selected for, even in a low usage setting, after their 
establishment. Our data underscores that a longitudinal 
framework is pivotal to obtaining a thorough epide­
miological understanding of the population dynamics 
of E coli. Furthermore, clones and clades can differ 
significantly between European countries that are 
resource similar, highlighting the need for country­specific 
intensified surveillance efforts to circumvent the threat 
posed by the current evolutionary trajectory of E coli 
causing bloodstream infections. The dominance of CC131 
also offers the possibility of targeted diagnostics in relation 
to infection control to restrict the spread of this high­risk 
multidrug resistant clone.
NORM isolates represent a subset of all bloodstream 
infection cases in Norway used for surveillance of 
antimicrobial resistance; however, NORM isolates are 
unbiased in terms of resistance profiles and are considered 
to be representative of all bloodstream infections in 
Norway.5 Although we only sampled the first 
22·5% of isolates annually, this subset should retain the 
representativeness of the NORM collection because E coli 




Ne (95% HPDI), 
per year*
Estimated incidence per million 
population in 2017† (95% CI)
Population size to 
incidence ratio in 2017
tMRCA (95% HPDI)
Clade A 3667 (1365–19872) 2004·6–2005·3 3147 (2909–3385) 20·58 (20·35–20·82) 0·006 1977 (1968–1983)
Clade B 2711 (1058–8812) 1989·8–1993·9 650 (608–692) 22·87 (22·63–23·10) 0·008 1926 (1884–1965)
Clade C1 730 (297–2382) 2002·8–2005·8 131 (126–137) 25·15 (24·92–25·39) 0·028 1993 (1988–1997)
Clade C2 883 (314–3284) 2004·7–2006·7 345 (326–364) 16·01 (15·77–16·24) 0·022 1992 (1985–1997)
Ne=growth rate. HPDI=highest posterior density interval. tMRCA=time to most recent common ancestor. *Total cases were estimated for each CC131 clade by adjusting the 
number of genomes of a clade by the proportion of total 2017 cases that were sequenced, before calculating incidence per million population in Norway in 2017. 
†During exponential time period.
Table: Median effective population size of clonal complex 131 clades
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bloodstream infections do not exhibit seasonality. 
Comparing two periods (2002–10 and 2011–17) or trends 
over time limits any bias in an individual year and the 
general trends in prevalence observed here concur with 
the NORM reports.5 For the analysis using phenotypic 
antimicrobial susceptibility testing (AST) data, we used 
categorical AST data reported in NORM based on the 
breakpoints for each year. Reported AST data were 
acquired by multiple methods during the time period 
(appendix 1 p 1). Thus, the breakpoints could not be 
calibrated over the whole study period. We used an 
earlier characterisation of ESBL­producers in the NORM 
surveillance, which showed that in 2017 100% of 
ESBL­producing E coli bloodstream infections were blaCTX-M­
positive,5 to justify using CTX­M­encoding genes as a proxy 
for ESBL producers, as such we did not include isolates in 
which only blaSHV or blaTEM were detected in the ESBL and 
CTX­M analyses. Finally, the published UK collection only 
represents isolates up until 2011. Given that the second 
half of our study (2011–17), during which 207 (74·5%) of all 
278 CC131 isolates were observed, extends well beyond 
sampling years of the UK report, it is possible that the 
importance of clade A within CC131 observed in Norway 
could have occurred in other locations since 2011.
Our study confirms that the clones of the extra­
intestinal pathogenic E coli population is under strong 
balancing selection and that resistance is not necessary 
for clonal success. However, we also show that even in a 
low antibiotic use setting, resistance to important 
antimicrobial classes has rapidly been selected for 
in a previously susceptible clade. This highlights the 
importance of future genomic surveillance in uncovering 
the complex ecology underlying multidrug resistance 
dissemination and competition, to support the design of 
strategies and interventions to control the spread of high­
risk multidrug resistant clones.
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